Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan Rhodes, ...

Edap TMS SA (EDAP) reports robust HIFU revenue growth and strategic advancements, despite facing operational challenges and a ...

Q4 2024 Earnings Call Transcript March 27, 2025 EDAP TMS S.A. beats earnings expectations. Reported EPS is $-0.05, ...

Reports revenue $21.5M, consensus $20.83M. “Our strong fourth quarter performance reflects our continued progress in establishing Focal One ...

A groundbreaking treatment for prostate cancer now available in Virginia aims to improve patient outcomes while minimizing side effects associated with traditional surgeries and radiation therapies.

Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One ...

I'm pleased to report another strong fourth-order performance which reflects our continued success in establishing Focal One as the leading robotic HIFU technology used by urologists in the ...